Find a Product

VX-809 (Lumacaftor)

VX-809 (Lumacaftor) is an experimental drug for the treatment of cystic fibrosis in development by Vertex Pharmaceuticals. VX-809 is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanine in position 508 is missing, is found in about 60% of cystic fibrosis patients in Europe, and in about 90% of persons with some mutation in the CFTR gene.

Catalog No. Size Price Quantity
92-1248 5 mg $325.00

For account specific pricing, please contact Customer Service at customerservicedrx@eurofins.com.
Description
VX-809 (Lumacaftor)
Compound Type
Agonist
Storage
-20°C
Source
Synthetic
Cells were plated in a 384-well plate and incubated for at least 4 hours at 37°C/5% CO₂ to allow the cells to attach. Cells were then stimulated with a control compound, using the assay conditions described below. Following stimulation, signal was detected using the PathHunter Detection Kit according to the recommended protocol.